OSE Immuno - Positive results from Ph1/2 study in renal transplant
OSE Immuno and Nantes University Hospital presented positive analysis from Ph1/2 study in renal transplant. Results were in line with the interim data presented in December 2023.A Phase 2 clinical trial of FR104/VEL-101 in patients undergoing kidney transplantation is under preparation by OSE's partner Veloxis Pharmaceuticals, which out-licensed FR104 for all transplant indications in 2021. OSE is eligible to receive up to EUR 315m in potential milestones and has so far received a EUR 7m upfront payment and a EUR 5m milestone payment following the IND acceptance.Small positive for OSE without impact on our valuation and investment case. We awaitOse Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.